Individual InvestorsEmployee Shareholders Institutional InvestorsPrivate Companies Accredited InvestorsSeed & Angel InvestorsAsset Managers & Hedge FundsFamily OfficesVenture Capital FirmsWealth Managers & RIAsWho We Serve Trading Data Liquidity Programs Retirement Individual InvestingForge MarketplaceFind new private company investment opportunities​Browse CompaniesInstitutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Data solutionsForge PriceA proprietary indicative price, calculated daily, for approximately 200 pre-IPO companiesForge DataAnalyze private markets via Forge’s intuitive web application​Index solutionsForge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Forge Thematic BasketsExplore focused views into key private market themesLiquidity ProgramsRetain and reward employees with company-sponsored liquidity solutions like tender offers and customized programsSelf-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRAWhat We Do All insights Reports and highlights News and trends Private market education Tips and tutorials Forge Investment OutlookPrivate Market UpdatesIPO calendarEmerging trendsPrivate company newsUpcoming IPOsAll guidesPrivate market basicsPrivate shares transactionsValuations, pricing and market trendsSelling in the private marketFAQsGlossaryCompany page and tradesProof of ownershipBid and ask submissionsForge fund offeringsInsights About UsLeadershipPeople & CultureCareers About
Log InSign Up
Who We Serve
What We Do
Insights
About
Apnimed

Apnimed IPO

$491.51M
Series D-1 Valuation, Mar 2026
Register for details
For more details on financing and valuation of private companies similar to Apnimed before its IPO, register or log in today.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Log In

Apnimed IPO date and status

2017
Founded
Jul 2026
S-1 Filed
Jul 2026
IPO Completed

Company details

Apnimed was founded in 2017 by Lawrence G. Miller and Luigi Taranto Montemurro. Apnimed has not officially endorsed a plan to participate in an IPO.

Apnimed is a pharmaceutical company developing oral pharmacologic treatments for obstructive sleep apnea and other related disorders. Per Forge data, Apnimed has raised a total of $207.8 million in funding over 5 rounds. Their latest funding was raised on Dec 23, 2022, from a Series C round. Key investors include Sectoral Asset Management, Morningside Venture Partners, and Alpha Wave Ventures.

These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.

Founded
2017
Headquarters
Cambridge, MA, United States
Founders
Andrew Wellman MD, Lawrence Miller MD, Luigi Montemurro MD
Forge Price 1
Price not available
Market Activity 2
Limited
Last Matched Price
Post-Money Valuation 3
$491.51M
Total Funding
$249.52M
Last Funding Round
Series D-1

Learn more about Apnimed

To invest in Apnimed pre-IPO

Can you invest in Apnimed pre-IPO?

You may invest in Apnimed as it is a public company listed on the NASDAQ with ticker APMD. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of Apnimed before it goes public?

You can no longer sell shares of Apnimed on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my Apnimed shares?

Forge can no longer determine the value of Apnimed shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is Apnimed a publicly traded company?

Apnimed became a public company following its IPO on 07/31/2026 and is now traded on the NASDAQ under the ticker APMD.

To learn more about Apnimed potential IPO

Will Apnimed go IPO?

Apnimed became a public company following its IPO on 07/31/2026 and is now traded on the NASDAQ under the ticker APMD.

What is Apnimed’s IPO price?

The IPO price of Apnimed is not currently available.

When was Apnimed founded?

Apnimed was founded in 2017.

What is Apnimed funding to date?

Apnimed has raised $249.52M to date.

Apnimed major investors

Alpha Wave Global
Morningside Group
Nexpoint
Sectoral Asset Management
Seligman Technology Group
Tao Capital Partners

Apnimed pre-IPO valuation and funding rounds

Funding history chart
Funding round and deals details
Funding Date Round Amount Raised Price per Share Post-Money Valuation 3 Key Investors
03/11/2026 Series D-1 $25M $13.03 $491.51M Undisclosed Investors
Price per Share
$ xx.xx
Shares Outstanding
1,918,452
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
04/23/2025 Series D $16.5M $13.02 $394.07M Undisclosed Investors
Price per Share
$ xx.xx
Shares Outstanding
1,267,200
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
12/22/2022 Series C-3 $79.75M $14.98 $366.58M Alpha Wave Ventures, Sectoral Asset Management, Seligman Investments, Tao Capital Partners
Price per Share
$ xx.xx
Shares Outstanding
5,325,451
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Alpha Wave Ventures, Sectoral Asset Management, Seligman Investments, Tao Capital Partners
05/04/2022 Series C-2 $25M $14.98 $268.69M Alpha Wave Ventures, Morningside Venture, Nexpoint, Sectoral Asset Management, Seligman Investments, Tao Capital Partners
Price per Share
$ xx.xx
Shares Outstanding
1,669,416
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Alpha Wave Ventures, Morningside Venture, Nexpoint, Sectoral Asset Management, Seligman Investments, Tao Capital Partners
05/04/2022 Series C-1 $37.5M $11.98 $268.69M Alpha Wave Ventures, Morningside Venture, Nexpoint, Sectoral Asset Management, Seligman Investments, Tao Capital Partners
Price per Share
$ xx.xx
Shares Outstanding
3,130,156
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Alpha Wave Ventures, Morningside Venture, Nexpoint, Sectoral Asset Management, Seligman Investments, Tao Capital Partners
03/25/2021 Series B $25M $11.96 $156.17M Morningside Venture, Seligman Investments, Tao Capital Partners
Price per Share
$ xx.xx
Shares Outstanding
2,089,669
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Morningside Venture, Seligman Investments, Tao Capital Partners
03/31/2020 Series A-2 $15M $8.61 $98.94M Morningside Venture
Price per Share
$ xx.xx
Shares Outstanding
1,741,370
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Morningside Venture
06/25/2018 Series A $25.77M $6.44 $57.26M Undisclosed Investors
Price per Share
$ xx.xx
Shares Outstanding
4,001,434
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Undisclosed Investors

Apnimed IPO news and media highlights

Independent IPO news coverage

Apnimed Announces Positive Topline Results for MARIPOSA Trial of AD109, Drug Candidate with the Potential to be the First Oral Therapy for Obstructive Sleep Apnea (OSA)

Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, announced today that it has secured $79.75 million in an oversubscribed financing round that extends its Series C financing to a total of $142.25 million.

Private companies exploring an IPO

See which private companies are preparing for the public market. Register to get full access to the latest secondary market pricing data.

Sector: Healthcare
Subsector: Biotech & Pharma
Trade Metrics Last Funding Round
Company Forge Price Last Matched Round Post-Money Valuation 3 Price Per Share Amount Raised
OURAOURANot available$ xx.xxSeries E$11B$53.57$900M
Affinia TherapeuticsAffinia TherapeuticsNot available$ xx.xxSeries C$156.61M$1.62$40M
OriginOriginNot available$ xx.xxNot available------

Private market movers

Track trading activity and investor momentum across thousands of private companies. Register to view last matched prices and additional transactional details.

Top Gainers

Company Forge Price (6M Change) Market Activity Last Matched
Ayar Labs Ayar Labs $89.26 +$59.46 (199.53%)Limited $xxx.xx
Kalshi Kalshi $962.28 +$629.16 (188.87%)High $xxx.xx
SandboxAQ SandboxAQ $41.35 +$26.10 (171.15%)High $xxx.xx
SambaNova Systems SambaNova Systems $78.81 +$47.82 (154.31%)High $xxx.xx
Stoke Space Stoke Space $119.38 +$69.46 (139.14%)Limited $xxx.xx

Artificial Intelligence (AI)

Company Forge Price Market Activity Last Matched
OpenAI OpenAI $721.85 +$0.15 (0.02%)High $xxx.xx
Anthropic Anthropic Not availableMedium $xxx.xx
Hugging Face Hugging Face Not availableLimited $xxx.xx
Anduril Anduril $122.93 -$0.11 (0.09%)High $xxx.xx
Databricks Databricks $264.90 +$22.86 (9.44%)High $xxx.xx

Forge, your trusted partner for pre-IPO insights and Apnimed data

Forge is the trusted platform for buying and selling pre-IPO shares. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.

Updated on: Aug 20, 2026

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions on Forge.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. Actively traded companies are companies with a high market activity with the highest post-money valuation in the same sector.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.